Kodiak Sciences (KOD) Earnings Date & Reports

Kodiak Sciences reported no revenue in Q4 or full-year 2025, aligning with its clinical-stage status. Net loss widened to $56.7 million ($1.04 per share) in Q4 from $44.1 million ($0.84 per share) in Q4 2024, versus consensus EPS estimate of approximately -$1.02 to -$1.05, roughly in line after adjusting for share count. Full-year loss reached $229.967 million ($4.32 per share), up from $176.207 million ($3.35 per share).

R&D expenses increased to $45.5 million in Q4 (from $31.8 million) and $182.4 million annually (from $126.1 million), fueled by clinical trials for DAYBREAK (wet AMD) and PEAK/PINNACLE (KSI-101 for macular edema). G&A fell to $12.0 million in Q4 (from $14.4 million), helped by sublease income, and $52.0 million yearly (from $60.8 million). Year-end cash rose to $209.9 million from $72 million at Q3 end, extending runway into 2027.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener today to enhance your stock discovery process.

Market Reaction and Investor Sentiment

Following the March 31, 2026 release, KOD shares traded around $37.98, up over 12% intraday, reflecting optimism over the cash position and clinical momentum despite wider losses. Sentiment centers on pipeline progress, including GLOW2 success and upcoming topline data, offsetting R&D-driven burn. Pre-release estimates pegged EPS at -$1.02 to -$1.05 with zero revenue, making results directionally aligned.

Forward Outlook and Key Factors to Monitor

Kodiak's $209.9 million cash hoard funds operations into 2027, providing stability amid no revenue. Key catalysts include Phase 3 topline readouts: DAYBREAK (Zenkuda and KSI-501 in wet AMD) in 3Q 2026, PEAK (KSI-101) in 4Q 2026, and PINNACLE in 2Q 2027. Positive GLOW2 data accelerates potential BLA for tarcocimab tedromer across wet AMD, RVO, and DR.

Investors should track R&D trends, as expenses rose on trial expansion. Manufacturing scale-up and regulatory interactions will be pivotal. Broader retinal market dynamics, including VEGF competitor durability, remain relevant. Cash burn management is crucial if readouts delay.

Monitor SEC filings for 10-K details and conference calls for guidance updates. Balanced execution on milestones could validate the ABC Platform's potential.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations